Previous 10 | Next 10 |
CAMBRIDGE, Mass. and NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. ...
Strategic partnership between Black Diamond and OpenEye aims to accelerate drug discovery efforts through cloud-based molecular dynamics technology CAMBRIDGE, Mass. and SANTA FE, N.M., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, a precision oncology medicine compa...
Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to initiate Phase 2 portion of MasterKey-01 study in second half of 2021 Pre-clinical data for BDTX-1535 presented at AACR Annual Meeting; program on track ...
CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., ...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded at a new 52-week low today of $8.79. So far today approximately 843,000 shares have been exchanged, as compared to an average 30-day volume of 602,000 shares. Black Diamond Therapeutics Inc is a precision oncology medicine company. It ...
Shares of Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded today at $9.25, breaking its 52-week low. Approximately 843,000 shares have changed hands today, as compared to an average 30-day volume of 624,000 shares. Black Diamond Therapeutics Inc. share prices have moved between a 52-...
Shares of Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded at a new 52-week low today of $9.97. This new low was reached on approximately average trading volume as 843,000 shares traded hands, while the average 30-day volume is approximately 746,000 shares. Potential upside of 6.6% e...
Shares of Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded today at $11.03, breaking its 52-week low. So far today approximately 843,000 shares have been exchanged, as compared to an average 30-day volume of 815,000 shares. In the past 52 weeks, Black Diamond Therapeutics Inc. share ...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded at a new 52-week low today of $11.92. So far today approximately 843,000 shares have been exchanged, as compared to an average 30-day volume of 972,000 shares. In the past 52 weeks, shares of Black Diamond Therapeutics Inc. have traded...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) traded at a new 52-week low today of $12.36. This new low was reached on approximately average trading volume as 843,000 shares traded hands, while the average 30-day volume is approximately 899,000 shares. Black Diamond Therapeutics Inc is a...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-07-31 09:00:12 ET Laura Prendergast from Raymond James issued a price target of $20.00 for BDTX on 2024-07-31 08:18:00. The adjusted price target was set to $20.00. At the time of the announcement, BDTX was trading at $5.91. The overall price target consensus is at ...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...